Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Clinical Study Evaluating the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Anlotinib as Second-Line Treatment for Patients With Driver Gene-Negative Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT07703228 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT07703228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07703228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Clinical Study Evaluating the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Anlotinib as Second-Line Treatment for Patients With Driver Gene-Negative Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 13, 2025
Completion date
March 13, 2028
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastases, nsclc (advanced non-small cell lung cancer), nsclc stage iiib~iv, second-line therapy